Related Experiment Video
Updated: Sep 16, 2025

12:33
Determination of Biofilm Initiation on Virus-infected Cells by Bacteria and Fungi
Published on: July 6, 2016
9.7K
Human herpesvirus 6B glycoprotein B postfusion structure, vulnerability mapping, and receptor recognition
Chu Xie1, Xin-Yan Fang2,3, Yuan-Tao Liu1
1State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
Plos Pathogens
|July 9, 2025
Summary
Human herpesvirus 6B (HHV-6B) glycoprotein B (gB) structure was determined, revealing unique features and potential therapeutic targets. This structural insight aids in developing new antiviral therapies and vaccines against HHV-6B infections.
Area of Science:
- Virology
- Structural Biology
- Immunology
Background:
- Human herpesvirus 6B (HHV-6B) poses a significant threat to immunocompromised individuals.
- Current therapeutic options and vaccines for HHV-6B are limited.
- Glycoprotein B (gB) is crucial for viral entry and a key target for antibody and vaccine development.
Purpose of the Study:
- To determine the cryo-EM structure of the HHV-6B gB ectodomain.
- To identify unique structural features and conserved residues across herpesviruses.
- To explore potential vulnerable sites on HHV-6B gB for therapeutic targeting.
Main Methods:
- Cryo-electron microscopy (cryo-EM) at 2.8 Å resolution.
- Comparative structural analysis with related herpesvirus gB proteins.
- Cross-binding assays using neutralizing antibodies (nAbs).
Main Results:
- The postfusion conformation of the HHV-6B gB ectodomain was resolved.
- Unique N-terminal features and the furin site were identified.
- Conserved residues across herpesviruses were mapped, and minimal cross-epitope recognition by heterologous nAbs was observed.
- Several potential vulnerable sites on HHV-6B gB were identified.
Conclusions:
- The determined structure provides critical insights into HHV-6B infection mechanisms.
- Understanding HHV-6B gB structure facilitates the development of targeted antiviral therapies and vaccines.
- The identified vulnerable sites offer promising avenues for future drug and vaccine design.

